Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States

Abstract

In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005. Rapid recognition and transport and quick treatment in the emergency department remain goals for further improving treatment rates.